ArticleMolecular biology reports2025
Nuclear respiratory factor-1 promotes CFLAR transcription in H9C2 cardiomyocytes, protecting them against hypoxia-induced apoptosis.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Design, synthesis, and mechanistic evaluation of propargylated salicylaldehyde derivatives as dual apoptosis-autophagy modulator for pancreatic cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Nuclear Respiratory Factor-1 Ameliorates Heart Failure by Suppressing Cardiomyocyte Pyroptosis-Associated Signaling Via the Downregulation of Gasdermin D and Caspase-1.Cardiology research · 2026Article
- Unraveling mitochondrial crosstalk: a new frontier in heart failure pathogenesis.Frontiers in cardiovascular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundInhibition of hypoxia-induced apoptosis in cardiomyocytes is crucial for heart failure treatment. Previous research suggests that nuclear respiratory factor-1 (NRF-1) protects hypoxic cardiomyocytes against apoptosis. In the present study, we hypothesized that NRF-1 regulates the expression of Caspase 8 and FADD-like apoptosis regulator (CFLAR) and thus contributes to the regulation of apoptosis in hypoxic cardiomyocytes. METHODS AND
resultsChromatin immunoprecipitation (ChIP) and Dual-Glo luciferase assays confirmed that NRF-1 binds to the Cflar gene promoter and regulates its transcriptional activity. Furthermore, the interactions between NRF-1 and CFLAR and their effects on H9C2 cardiomyocytes apoptosis were tested under hypoxic conditions. Using the BioTek imaging system, we showed that CFLAR siRNA reversed the effects of NRF-1 overexpression on cell growth and death; CFLAR siRNA markedly increased the apoptosis rates and the activities of Caspase-3 and Caspase-8 in NRF-1-overexpressing cells. Conversely, in NRF-1-knockdown cells, CFLAR overexpression suppressed hypoxia-induced apoptosis. Western blot analysis showed that NRF-1-mediated regulation of CFLAR expression primarily influences the protein levels of cleaved Caspase-8 and tBid, without any significant differences in Bid, Bcl-2, and Bax expression.
conclusionsWe demonstrated that NRF-1 directly regulates CFLAR expression, thereby inhibiting the death receptor pathway, and ultimately, protects H9C2 cardiomyocytes from hypoxia-induced apoptosis. Our findings will provide novel insights into the molecular mechanisms underlying the protective role of NRF-1 and support its potential to serve as a therapeutic target for ameliorating heart failure.
Indexed as
Identifiers
40478441What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.